AHA/ASA guideline recommendations for prevention of stroke
< AHA
|
Ischemic Stroke Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
AHA/ASA guideline recommendations for prevention of stroke On the Web |
|
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for prevention of stroke |
|
FDA on AHA/ASA guideline recommendations for prevention of stroke |
|
CDC on AHA/ASA guideline recommendations for prevention of stroke |
|
AHA/ASA guideline recommendations for prevention of stroke in the news |
|
Blogs on AHA/ASA guideline recommendations for prevention of stroke |
|
Risk calculators and risk factors for AHA/ASA guideline recommendations for prevention of stroke |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];
2014 AHA/ASA Guidelines for the Primary Prevention of Stroke[1]
Genetic Factors: Recommendations
| Class III (Harm) |
| "1.Genetic screening to determine risk for myopathy is not recommended when initiation of statin therapy is being considered (Level of Evidence: C)" |
| "2. Genetic screening of the general population for the prevention of a first stroke is not recommended (Level of Evidence: C)" |
| "3.Screening for intracranial aneurysms in every car- rier of autosomal-dominant polycystic kidney disease or Ehlers-Danlos type IV mutations is not recommended (Level of Evidence: C)" |
| "4. Noninvasive screening for unruptured intracranial aneurysms in patients with no more than 1 relative with SAH or intracranial aneurysms is not recommended (Level of Evidence: C)" |
| Class IIa |
| "1. Obtaining a family history can be useful to help identify persons who may be at increased risk of stroke (Level of Evidence: A)" |
| Class IIb |
| "1. Referral for genetic counseling may be considered for patients with rare genetic causes of stroke (Level of Evidence: C)" |
| "2. Treatment of Fabry disease with enzyme replacement therapy might be considered, but has not been shown to reduce the risk of stroke, and its effectiveness is unknown (Level of Evidence: C)" |
| "3. Noninvasive screening for unruptured intracranial aneurysms in patients with ADPKD and ≥1 relatives with ADPKD and SAH or intracranial aneurysm may be considered(Level of Evidence: C)" |
| "4. Noninvasive screening for unruptured intracranial aneurysms in patients with ≥2 first-degree relatives with SAH or intracranial aneurysms might be reasonable (Level of Evidence: C)" |
| "5. Noninvasive screening for unruptured intracranial aneurysms in patients with cervical fibromuscular dysplasia may be considered(Level of Evidence: C)" |
| "6.Pharmacogenetic dosing of vitamin K antagonists may be considered when therapy is initiated(Level of Evidence: C)" |
Physical Inactivity: Recommendations
| Class I |
| "1.Physical activity is recommended because it is associated with a reduction in the risk of stroke (Level of Evidence: B)" |
| "2. Healthy adults should perform at least moderate- to vigorous-intensity aerobic physical activity at least 40 min/d 3 to 4 d/wk(Level of Evidence: B)" |
Dyslipidemia: Recommendations
| Class I |
| "1. In addition to therapeutic lifestyle changes, treat- ment with an HMG coenzyme-A reductase inhibitor (statin) medication is recommended for the primary prevention of ischemic stroke in patients estimated to have a high 10-year risk for cardiovascular events as recommended in the 2013 “ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults”(Level of Evidence: A)" |
References
- ↑ 2014 AHA/ASA Guidelines for the Primary Prevention of Stroke http://stroke.ahajournals.org/content/early/2014/10/28/STR.00000000000000467 Accessed on November 17, 2016